Dexmedetomidine Ameliorates Myocardial Ischemia‐Reperfusion Injury by Inhibiting MDH2 Lactylation via Regulating Metabolic Reprogramming
2024

Dexmedetomidine Helps Heart Recovery After Surgery

Sample size: 60 publication 10 minutes Evidence: high

Author Information

Author(s): She Han, Hu Yi, Zhao Guozhi, Du Yunxia, Wu Yinyu, Chen Wei, Li Yong, Wang Yi, Tan Lei, Zhou Yuanqun, Zheng Jie, Li Qinghui, Yan Hong, Mao Qingxiang, Zuo Deyu, Liu Liangming, Li Tao

Primary Institution: Army Medical University

Hypothesis

Can dexmedetomidine reduce myocardial ischemia-reperfusion injury through metabolic reprogramming?

Conclusion

Dexmedetomidine reduces lactate levels and improves mitochondrial function, helping to prevent heart damage after surgery.

Supporting Evidence

  • Dexmedetomidine significantly reduced postoperative cardiac injury biomarkers.
  • Metabolomics showed that dexmedetomidine regulates metabolic pathways related to heart function.
  • Dex treatment improved mitochondrial function in rat models of myocardial ischemia-reperfusion injury.
  • Dex inhibited lactate production and improved cardiac contractility.
  • Dex downregulated MDH2 lactylation, which is linked to heart injury.
  • Phosphorylation of NR3C1 was enhanced by dexmedetomidine, leading to reduced PDK4 levels.
  • Dex reduced ferroptosis in cardiomyocytes, contributing to its cardioprotective effects.
  • Overall, dexmedetomidine provides new therapeutic targets for treating myocardial ischemia-reperfusion injury.

Takeaway

This study shows that a medicine called dexmedetomidine can help protect the heart during surgery by lowering harmful substances and helping the heart work better.

Methodology

The study involved 60 patients with heart valve disease, who were randomly assigned to receive dexmedetomidine or a control treatment, with blood samples collected for analysis.

Potential Biases

Potential biases in patient selection and treatment assignment.

Limitations

The study was limited to patients undergoing valve replacement surgery and may not generalize to other populations.

Participant Demographics

Patients diagnosed with heart valve disease undergoing valve replacement surgery.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1002/advs.202409499

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication